IQ-AI Balance Sheet Health

Financial Health criteria checks 4/6

IQ-AI has a total shareholder equity of £433.2K and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £1.1M and £641.5K respectively.

Key information

Debt to equity ratio

UK£0

Debt

Interest coverage ratio	n/a
Cash	UK£186.12k
Equity	UK£433.19k
Total liabilities	UK£641.54k
Total assets	UK£1.07m

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 5Y1's short term assets (£435.6K) do not cover its short term liabilities (£641.5K).

Long Term Liabilities: 5Y1 has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: 5Y1 is debt free.

Reducing Debt: 5Y1 had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5Y1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 5Y1 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 17.3% each year.

IQ-AI Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

IQ-AI Shares Cease Trading on the OTCQB

IQ-AI Ordinary Shares to Be Deleted from Other OTC

Recent updates

IQ-AI Limited Announces Board Changes

Braveheart Investment Group plc (AIM:BRH) acquired 29.51% stake in IQ-AI Limited (LSE:IQAI) from Trevor Brown and Free Association Books Limited for £0.719 million.

New minor risk - Financial position

IQ-AI Ltd. Provides Update on Phase 1 Update

IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024

IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024

Full year 2023 earnings released: UK£0.003 loss per share (vs UK£0.003 loss in FY 2022)

New minor risk - Financial data availability

IQ-AI Limited has completed a Follow-on Equity Offering in the amount of £0.371 million.

IQ-AI Limited has filed a Follow-on Equity Offering in the amount of £0.4 million.

New minor risk - Shareholder dilution

IQ-AI Applies for FDA Pediatric Rare Disease Designation

IQ-AI Shares Cease Trading on the OTCQB

First half 2023 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in 1H 2022)

Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.003 loss in FY 2021)

No independent directors

First half 2022 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2021)

Imaging Biometrics, Llc (Ib),A Subsidiary of Iq-Ai Limited Submits Fda 510(K) Application for Ib Zero G™

IQ-AI Limited, Annual General Meeting, May 30, 2022

Full year 2021 earnings released: UK£0.003 loss per share (vs UK£0.005 loss in FY 2020)

No independent directors

IQ-AI Prepares for Phase I Clinical Trial Launch

IQ-AI Limited Receives European Patent for 'Multiparameter Perfusion Imaging with Leakage Correction'

Non-Executive Chairman Qu Li has left the company

First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.003 loss in 1H 2020)

IQ-AI Ordinary Shares to Be Deleted from Other OTC

IQ-AI Limited Announces Its Synthetic T1+C Software Application Was Awarded A Patent by the U.S. Patent and Trademark Office

Full year 2020 earnings released: UK£0.005 loss per share (vs UK£0.005 loss in FY 2019)

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies